Home > Articles > Published articles > Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations > Comments
 
 
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations - Wilson, B.E. (University of New South Wales) ; Desnoyers, A. (Princess Margaret Cancer Centre. Department of Medical Oncology. University of Toronto) ; Nadler, M.B. (Princess Margaret Cancer Centre. Department of Medical Oncology. University of Toronto) ; Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ; Amir, Eitan (Princess Margaret Cancer Centre. Department of Medical Oncology. University of Toronto) ; Universitat Autònoma de Barcelona
 
Comments (0) | Reviews (0)
Start a discussion about any aspect of this document.

 Subscribe to this discussion. You will then receive all new comments by email.

Add comment


Once logged in, authorized users can also attach files.
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.
          You can use some HTML tags: <a href>, <strong>, <blockquote>, <br />, <p>, <em>, <ul>, <li>, <b>, <i>

Similar records

UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with